Showing 4,861 - 4,880 results of 34,735 for search '(( 50 ((we decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( i wt decrease ))', query time: 1.23s Refine Results
  1. 4861
  2. 4862

    Atrial and ventricular connexins and sodium channel genes expression levels in wt and Ts65Dn mice. by Matthieu Raveau (160575)

    Published 2012
    “…Ts65Dn show an overall decrease in connexin and sodium channel mRNA expression except for <i>Cx45</i> and <i>Cx30.2</i> in the atria. …”
  3. 4863

    Cytoplasmic deadenylase Ccr4 is required for translational repression of <i>LRG1</i> mRNA in the stationary phase by Duong Long Duy (3775429)

    Published 2017
    “…In the log-phase <i>ccr4Δ</i> mutant cells, <i>LRG1</i> poly(A) tail was longer and <i>LRG1</i> mRNA level was higher than those in the log-phase wild-type (WT) cells. …”
  4. 4864

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  5. 4865

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  6. 4866

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  7. 4867

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  8. 4868

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  9. 4869

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  10. 4870

    Methodology. by Scott John (228011)

    Published 2024
    “…Upon binding of lactate YFP and CFP move farther apart, the intensity of YFP fluorescence decreases while that of CFP increases. This leads to a decrease in the YFP/CFP FRET ratio. …”
  11. 4871
  12. 4872

    T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1 by Antonella Bresin (5819432)

    Published 2018
    “…In particular, the colony-forming efficiency (CFE) and the insulin-like growth factor 1 (IGF1)-induced proliferation are dramatically impaired, while apoptosis is increased, in KCs from <i>Tcl1-/-</i> mice when compared to WT. …”
  13. 4873
  14. 4874
  15. 4875
  16. 4876

    Nur77 expression by thymocytes and peripheral T cells in WT and Nur77Tg mice. by Ran Tao (81449)

    Published 2008
    “…Thymuses from WT or Nurr77Tg mice were stained with CD4, CD8, CD25 and CD44 Abs; left upper panel showed the proportions of single positive (CD4+ or CD8+), double positive and double negative cells, and left lower panel shows analysis of the double negative (DN) population 1–4 based on CD44 and CD25 expression. …”
  17. 4877
  18. 4878
  19. 4879
  20. 4880